Unknown

Dataset Information

0

IGF2BP2 stabilized FBXL19-AS1 regulates the blood-tumour barrier permeability by negatively regulating ZNF765 by STAU1-mediated mRNA decay.


ABSTRACT: Blood-tumour barrier (BTB) has been known to significantly attenuate the efficacy of chemotherapy for glioma. In this report, we identified that insulin-like grown factor 2 mRNA-binding protein 2 (IGF2BP2) was over-expressed in glioma microvessel and glioma endothelial cells (GECs). Knockdown of IGF2BP2 decreased the expression of lncRNA FBXL19-AS1 and tight junction-related proteins, thereby promoting BTB permeability. FBXL19-AS1 was over-expressed and more enriched in the cytoplasm of GECs. In addition, FBXL19-AS1 could bind to 3'-UTR of ZNF765 mRNA and down-regulate ZNF765 mRNA expression through STAU1-mediated mRNA decay (SMD). The low expression of ZNF765 was discovered in GECs and verified to increase BTB permeability by inhibiting the promoter activities of tight junction-related proteins. Meanwhile, ZNF765 also inhibited the transcriptional activity of IGF2BP2, thereby forming a feedback loop in regulating the BTB permeability. Single or combined application of silenced IGF2BP2 and FBXL19-AS1 improved the delivery and antitumor efficiency of doxorubicin (DOX). In general, our study revealed the regulation mechanism of IGF2BP2/FBXL19-AS1/ZNF765 axis on BTB permeability, which may provide valuable insight into treatment strategy for glioma.

SUBMITTER: Liu X 

PROVIDER: S-EPMC7714532 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9844485 | biostudies-literature
| S-EPMC3073508 | biostudies-literature
| S-EPMC7744744 | biostudies-literature
| S-EPMC6933377 | biostudies-literature
| S-EPMC6997171 | biostudies-literature
| S-EPMC7183103 | biostudies-literature
| S-EPMC7256440 | biostudies-literature
| S-EPMC11181683 | biostudies-literature
| S-EPMC9192260 | biostudies-literature
| S-EPMC9677966 | biostudies-literature